Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non-small cell lung cancer from proteomic profiling of circulating extracellular vesicles.
Masahiro TorasawaHidehito HorinouchiShigehiro YagishitaHirofumi UtsumiKeitaro OkudaDaisuke TakekoshiSaburo ItoHiroshi WakuiSaori MurataSawako KakuKae OkumaYuji MatsumotoYuki ShinnoYusuke OkumaTatsuya YoshidaYasushi GotoNoboru YamamotoJun ArayaYuichiro OheYu FujitaPublished in: Thoracic cancer (2023)
Circulating EV-RELA may be a predictive marker for symptomatic pneumonitis in patients with LA-NSCLC treated with durvalumab.